University of Vermont Cancer Center Member Profile
David Seward, MD, PhD
Assistant Professor, Pathology and Laboratory Medicine-Research
Full Member
Cancer Cell (CC)
Academic Interests
Each year lung cancer kills more people in the United States than breast, colorectal and prostate cancers combined. Immunotherapies, including anti-PD-1 monoclonal antibodies, may reduce lung cancer morbidity and mortality, but science can’t yet accurately predict which patients will benefit. The goal of the Seward Lab is to delineate the molecular mechanisms linking STK11 loss with anti-PD-1 therapy resistance in KRAS-driven lung adenocarcinoma and exploit that knowledge to restore sensitivity to current therapies while working to identify new treatment strategies.
Other Titles, Distinctions and Appointments
The Elmer R. Huber Early Career Green and Gold Professor in Pathology and Laboratory Medicine
Each year lung cancer kills more people in the United States than breast, colorectal and prostate cancers combined. Immunotherapies, including anti-PD-1 monoclonal antibodies, may reduce lung cancer morbidity and mortality, but science can’t yet accurately predict which patients will benefit. The goal of the Seward Lab is to delineate the molecular mechanisms linking STK11 loss with anti-PD-1 therapy resistance in KRAS-driven lung adenocarcinoma and exploit that knowledge to restore sensitivity to current therapies while working to identify new treatment strategies.
Other Titles, Distinctions and Appointments
The Elmer R. Huber Early Career Green and Gold Professor in Pathology and Laboratory Medicine